Aficamten improves symptom burden and exercise capacity in patients with non-obstructive HCM
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented in a Hot Line session today…